Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lilly Provides Update on Next Steps for Solanezumab

Published: Thursday, December 13, 2012
Last Updated: Thursday, December 13, 2012
Bookmark and Share
Eli Lilly and Company provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer's disease.

Following discussions with regulators in the U.S., Europe and Canada, Lilly plans to conduct an additional Phase 3 study of solanezumab in patients with mild Alzheimer's disease. Additional details, including study design and length, are still being determined. Lilly expects to initiate this study no later than Q3 2013.

Based on recent meetings with the U.S. Food and Drug Administration (FDA), Lilly does not intend to submit a Biologics License Application (BLA) at this time in the U.S. based solely on the existing analyses of data from the EXPEDITION studies. Lilly will continue to analyze and discuss the data from the two, Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION studies with regulators globally to determine the regulatory paths forward in different regions. It is possible that different courses of action could be taken in different jurisdictions.

Independent analyses of the Phase 3 solanezumab EXPEDITION data were conducted by the Alzheimer's Disease Cooperative Study (ADCS), an academic research consortium, and presented at the annual meeting of the American Neurological Association (ANA) on Oct. 8, 2012, and at the Clinical Trial on Alzheimer's Disease (CTAD) meeting on Oct. 29, 2012.

"Based on both the independent analyses by the ADCS, as well as our own," said Eric Siemers, senior medical director of Lilly's Alzheimer's disease team, "we believe the results demonstrating a slowing of cognitive decline in patients with mild Alzheimer's disease treated with solanezumab are the first data from Phase 3 clinical trials that support the amyloid hypothesis."

"We remain encouraged and excited by the solanezumab data," said David Ricks, senior vice president and president, Lilly Bio-Medicines. "We are committed to working with the FDA and other regulatory authorities to bring solanezumab to the millions of patients and caregivers suffering from this devastating disease who urgently need this potential treatment."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Eli Lilly, AstraZeneca to Continue Clinical Trial for Early Alzheimer's
Phase 2/3 trial of AZD3293, an oral potent small molecule BACE inhibitor, will continue to Phase 3 after positive interim safety data.
Monday, April 11, 2016
Eli Lilly Fly to the ISS for R&D
Eli Lilly & Company is willing to go the extra mile for research and development—230 miles straight up, in fact—to the International Space Station (ISS).
Monday, April 11, 2016
FDA Approval for Lilly's Gastric Cancer Drug
CYRAMZA now approved both as a single-agent treatment and in combination with chemotherapy.
Monday, November 10, 2014
Lilly, Zymeworks Expand Strategic Licensing and Collaboration Agreement
Zymeworks Inc. and Eli Lilly and Company are expanding their existing licensing and collaboration agreement.
Friday, October 24, 2014
Lilly to Close One of Three Manufacturing Operations in Puerto Rico
Manufacturing at Guayama will conclude while investments continue in Carolina.
Friday, October 17, 2014
Lilly to Acquire Novartis Animal Health
$5.4 billion deal creates world's second-largest animal health company.
Thursday, September 18, 2014
Lilly Invests $700M in Insulin Manufacturing Capacity
The investments are a direct response to the growing diabetes epidemic.
Friday, November 15, 2013
Applied NeuroSolutions Announces Renewal of Alzheimer’s Disease Drug Discovery Collaboration with Eli Lilly
Lilly will pay $250,000 to Applied NeuroSolutions for the one-year collaboration renewal.
Wednesday, December 09, 2009
Lilly Completes Acquisition of ImClone Systems
The acquisition will broaden Lilly's portfolio of marketed cancer therapies and oncology pipeline with up to three targeted therapies in Phase III in 2009.
Tuesday, November 25, 2008
Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
The collaboration will apply Deciphera's phylomechanics platform with Lilly's expertise to study B-Raf kinase inhibitors for cancer treatments.
Monday, October 06, 2008
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Late-stage IDENTITY study of once-daily, oral agent is now enrolling patients.
Wednesday, April 02, 2008
Lilly and BioMS Medical Announce Global Licensing and Development Agreement
Lilly to acquire exclusive rights to late-stage molecule for the treatment of multiple sclerosis.
Wednesday, December 19, 2007
Lilly Breast Cancer Studies Explore Potential Role of Pharmacogenomics in Customizing Chemotherapy
Lilly has unveiled two breast cancer studies involving pharmacogenomics and its chemotherapies GEMZAR® (gemcitabine HCl) and ALIMTA® (pemetrexed).
Tuesday, June 06, 2006
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Gene Regulation in Brain May Explain Repetitive Behaviors in Rett Syndrome Patients
The research could be a key step in developing treatments to eliminate symptoms that drastically impair the quality of life in Rett patients.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!